Cnbx Pharmaceuticals Inc. (CNBX) intrinsic value & 10-year financials
Cnbx Pharmaceuticals Inc. (CNBX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 1.8% a year to $0, with an average return on invested capital of -425.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $12.7K
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- 1.8%
- ROIC (10-yr avg)
- -425.1%
- Free cash flow (FY2025)
- —
CNBX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$314.0K | $0.00 | — | — | 12.6% |
| FY2024 | $130.1K | -$695.2K | -$0.01 | — | -448.3% | 30.9% |
| FY2023 | $410.2K | -$3.7M | -$0.14 | — | -227.1% | 203.3% |
| FY2022 | $30.0K | -$3.7M | -$0.17 | — | -9860.4% | -4289.4% |
| FY2021 | $0 | -$3.2M | -$0.00 | — | — | -178.9% |
| FY2020 | $7.2K | -$7.5M | — | — | -42524.1% | -90.5% |
| FY2019 | $9.8K | $1.1M | — | — | -33563.0% | 13.0% |
| FY2018 | $9.6K | -$3.8M | — | — | -39670.1% | -135.3% |
| FY2017 | $5.7K | -$1.9M | — | — | -32616.1% | -156.5% |
| FY2016 | $112.5K | -$1.6M | — | — | -249.5% | 339.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CNBX Pharmaceuticals Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CNBX Pharmaceuticals Inc. has historically struggled to out-earn its cost of capital, averaging just -21.0% ROIC.
CNBX Pharmaceuticals Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CNBX Pharmaceuticals Inc. is modeled at 1.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.00 per share.